HighCape Partners

Modifi Bio develops oncology therapeutics based on direct DNA modification. The company pursues a platform that modifies tumor DNA to render cancer cells irreparable while preserving healthy cells, aiming to disrupt conventional oncology drug development.

Elutia is a commercial-stage regenerative medicine company dedicated to advancing surgical outcomes for patients receiving implantable medical devices. The company focuses on developing a new generation of differentiated products through its proprietary tissue processing platforms, resulting in a portfolio of advanced regenerative medical products that closely mimic natural biological materials. Elutia operates across several segments, including Device Protection, Women's Health, and Cardiovascular, with the Women's Health segment generating the majority of its revenue. Its products aim to address unmet clinical needs by promoting healthy tissue formation and reducing complications associated with medical device implants, such as scar-tissue formation and capsular contraction.

Modifi Bio develops oncology therapeutics based on direct DNA modification. The company pursues a platform that modifies tumor DNA to render cancer cells irreparable while preserving healthy cells, aiming to disrupt conventional oncology drug development.

Wellinks specializes in wearable health technologies designed to enhance clinical outcomes. Founded in 2014, the company is renowned for its innovative smart strap that monitors scoliosis brace wear duration and tightness, empowering patients, parents, and doctors with real-time data for informed treatment decisions.

Cybrexa Therapeutics is a biotechnology company focused on developing an innovative class of small molecule DNA repair inhibitors aimed at improving cancer treatment. Founded in 2016 and based in New Haven, Connecticut, Cybrexa utilizes a proprietary peptide-based technology that specifically targets the tumor microenvironment. This approach allows for enhanced drug delivery and increased therapeutic efficacy, particularly when combined with existing chemotherapies and radiotherapies. By enabling the safe administration of higher drug doses, Cybrexa's therapeutics aim to expand the efficacy of current anticancer agents and address significant unmet medical needs in oncology. The company's novel platform has the potential to redefine drug delivery paradigms and enhance patient outcomes in cancer care.

Alphina Therapeutics is a biotechnology company specializing in the development of targeted cancer therapies. It focuses on leveraging proprietary biomarkers and insights to identify and treat cancer patients with NAD Metabolic Deficiencies (NMD). The company aims to develop companion diagnostics and translate these findings into clinical applications.

Flyp Nebulizer, the medical device is reinvented by Weblinks for respiratory care around the people who need it most. It works at ultrasonic speed to create a fine aerosol of medication. Flyp Nebulizer works quickly to deliver treatment within 7-minute average.

Wellinks specializes in wearable health technologies designed to enhance clinical outcomes. Founded in 2014, the company is renowned for its innovative smart strap that monitors scoliosis brace wear duration and tightness, empowering patients, parents, and doctors with real-time data for informed treatment decisions.

Cybrexa Therapeutics is a biotechnology company focused on developing an innovative class of small molecule DNA repair inhibitors aimed at improving cancer treatment. Founded in 2016 and based in New Haven, Connecticut, Cybrexa utilizes a proprietary peptide-based technology that specifically targets the tumor microenvironment. This approach allows for enhanced drug delivery and increased therapeutic efficacy, particularly when combined with existing chemotherapies and radiotherapies. By enabling the safe administration of higher drug doses, Cybrexa's therapeutics aim to expand the efficacy of current anticancer agents and address significant unmet medical needs in oncology. The company's novel platform has the potential to redefine drug delivery paradigms and enhance patient outcomes in cancer care.

ZipLine Medical, Inc. is a medical device company that specializes in developing and marketing non-invasive skin closure solutions. Founded in 2007 and based in Campbell, California, the company focuses on its flagship product, the Zip Surgical Skin Closure, which is designed for use across various medical specialties, including cardiology, orthopedics, and emergency medicine. Utilizing its innovative PRELOC technology platform, ZipLine Medical provides a method for rapid skin closure that combines the speed of staples with the aesthetic benefits of sutures, while minimizing the risk of surgical site infections and reducing scar-promoting tension. This technology aims to enhance surgical outcomes by delivering uniform closure forces along incisions, making it applicable to a wide range of surgical procedures. ZipLine Medical operates as a subsidiary of Stryker Corporation.

Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.

Cybrexa Therapeutics is a biotechnology company focused on developing an innovative class of small molecule DNA repair inhibitors aimed at improving cancer treatment. Founded in 2016 and based in New Haven, Connecticut, Cybrexa utilizes a proprietary peptide-based technology that specifically targets the tumor microenvironment. This approach allows for enhanced drug delivery and increased therapeutic efficacy, particularly when combined with existing chemotherapies and radiotherapies. By enabling the safe administration of higher drug doses, Cybrexa's therapeutics aim to expand the efficacy of current anticancer agents and address significant unmet medical needs in oncology. The company's novel platform has the potential to redefine drug delivery paradigms and enhance patient outcomes in cancer care.

Elutia is a commercial-stage regenerative medicine company dedicated to advancing surgical outcomes for patients receiving implantable medical devices. The company focuses on developing a new generation of differentiated products through its proprietary tissue processing platforms, resulting in a portfolio of advanced regenerative medical products that closely mimic natural biological materials. Elutia operates across several segments, including Device Protection, Women's Health, and Cardiovascular, with the Women's Health segment generating the majority of its revenue. Its products aim to address unmet clinical needs by promoting healthy tissue formation and reducing complications associated with medical device implants, such as scar-tissue formation and capsular contraction.

ZipLine Medical, Inc. is a medical device company that specializes in developing and marketing non-invasive skin closure solutions. Founded in 2007 and based in Campbell, California, the company focuses on its flagship product, the Zip Surgical Skin Closure, which is designed for use across various medical specialties, including cardiology, orthopedics, and emergency medicine. Utilizing its innovative PRELOC technology platform, ZipLine Medical provides a method for rapid skin closure that combines the speed of staples with the aesthetic benefits of sutures, while minimizing the risk of surgical site infections and reducing scar-promoting tension. This technology aims to enhance surgical outcomes by delivering uniform closure forces along incisions, making it applicable to a wide range of surgical procedures. ZipLine Medical operates as a subsidiary of Stryker Corporation.

Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.